Benzomorphans useful as NMDA receptor antagonists

Details Benzomorphans useful as NMDA receptor antagonists Benzomorphans useful as NMDA receptor antagonists

1992-12-16

1994-10-11

Richter, Johann

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

546 97, C07D22126, A61K 31445

Patent

active

053547586

ABSTRACT:
Compounds of the formula I ##STR1## are disclosed. In this formula, R is a member selected from the group consisting of --CR.sub.1 R.sub.2 R.sub.3, hydroxy, an alkoxy group having 1 to 4 carbon atoms and --NR.sub.4 R.sub.5, in which at most one of R.sub.1, R.sub.2 and R.sub.3 is hydrogen and the remainder are each independently selected from the group consisting of an alkyl group having 1 to 4 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkynyl group having 2 to 4 carbon atoms, a cycloalkyl group having 3 to 7 carbon atoms, a cycloalkylalkyl having 4 to 9 carbon atoms and a 3 to 6 membered cyclic ether; R.sub.4 and R.sub.5 are each independently hydrogen or an alkyl group having 1 to 4 carbon atoms; R.sub.6 and R.sub.7 are each independently hydrogen or an alkyl group having 1 to 4 carbon atoms; and R.sub.8 is hydrogen, an alkyl group having 1 to 4 carbon atoms, hydroxy, an alkoxy group having 1 to 4 carbon atoms or halogen. Salts of these compounds are also disclosed. Also disclosed are pharmaceutical compositions of these compounds with a pharmaceutically acceptable carrier, the use of these materials as N-methyl-D-aspartate receptor antagonists, processes for preparing these compounds and salts, and methods to treat cerebral diseases by administering an effective amount of these compounds, salts or compositions.

REFERENCES:
patent: 3382249 (1968-05-01), Albertson
patent: 3634433 (1972-01-01), Moriyama et al.
patent: 4108857 (1978-08-01), Albertson
patent: 5145965 (1992-09-01), Allen et al.
Carroll et al., "Enantiomeric N-substituted N-normetazocines: a comparative study of affinities at .sigma., PCP, and .mu. opioid receptors" J. Med. Chem. (1992) 35:2812-2818.
Gill et al., "Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the Gerbil" J. Neurosci. (1987) 7(10):3343-3349.
Goldberg et al., "Dextrorphan and dextromehtorphan attenuate hypoxic injury in neuronal culture" Neurosci. Lett. (1987) 80:11-15.
Hori et al., "Synthesis of some N-substituted 1,2,3,4,5,6-hexahydro-2,6-methzazocines (6,7-benzomorphans)" Chem. Pharm. Bull. (1985) 33(4):1707-1710.
McDonald et al., "MK-801 protects the neonatal brain from hypoxic-ischemic damage" Eur. J. Pharmacol. (1987) 140:359-361.
Meldrum, B., "Excitatory amino acid antagonists as potential therapeutic agents" Neurotoxins and Their Pharmaceutical Implications, Jenner, P., Ed., (1987) Raven Press, New York. pp. 33-53.
Rothman et al., "Ketamine protects hippocampal neurons from anoxia in vitro" Neurosci. (1987) 21(3):673-687.

Affiliated with

Also associated with

Rating

Benzomorphans useful as NMDA receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzomorphans useful as NMDA receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzomorphans useful as NMDA receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1658791